



Alzinova presents at investor meetings in March

Alzinova AB (publ) will present the company to investors at two capital market events in March 2024. First out is Penser By Carnegie's company day on 7 March, followed by Redeye Theme: Alzheimer on 21 March.

Penser by Carnegie company day, March 7

At Penser by Carnegie's company day on 7 March, Alzinova's CEO Kristina Torfgård will present the company and the latest developments. The presentation, which will be broadcast live, will be held at 9.05-9.30 and can be viewed at the following link: https://www.youtube.com/playlist?list=PLFeVXfrcmwBBZO_h_NjsLu2mH3-KYatyIY

Redeye Theme: Alzheimer's disease, March 21

Drug development in the field of Alzheimer's disease is an ongoing hot topic and society is now facing an important paradigm shift with the commercialisation of the first disease-modifying therapies. Redeye has invited Alzinova and two other companies - three prominent Swedish Alzheimer's companies - to a panel discussion to talk about the science behind their drug candidates, the remaining need and what it will take to successfully launch a new generation of Alzheimer's drugs. CEO Kristina Torfgård will participate in the panel. Access the event here: <https://www.redeye.se/events/975970/redeye-theme-alzheimer-2?tab=attendingcompanies>

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com



Attachments

Alzinova presents at investor meetings in March